Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05093478 · ClinicalTrials.gov registry record · Phase 3

The Prevalence of Local Immunoglobulin E (IgE) Elevation and Its Effect on Intranasal Capsaicin Therapy in the Non-allergic Rhinitis Population

A Phase 3 study, sponsored by The University of Texas Health Science Center, Houston.

Completed
Registry status
Phase 3
Development phase
28
Enrollment target

NCT05093478: Completed Phase 3 study, sponsored by The University of Texas Health Science Center, Houston.

NCT05093478 is a Phase 3 study that has completed, run by The University of Texas Health Science Center, Houston. The registered enrollment target is 28 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05093478, a Phase 3 study, has completed, sponsored by The University of Texas Health Science Center, Houston.

COMPLETED
Registry status
Phase 3
Development phase
28 participants
Enrollment target

Study Summary

The purpose of this study to determine the therapeutic response of non-allergic rhinitis patients that have been subtyped as non-allergic rhinitis with local IgE elevation or non-allergic rhinopathy to intranasal capsaicin based on visual analog scale and optical rhinometry, to determine the prevalence of non-allergic rhinitis with local IgE elevation in this study's cohort of patients with non-allergic rhinitis identified by rhinitis history and negative skin testing for allergic rhinitis, and to determine the change, if any, in intranasal IgE levels after capsaicin treatment.

Primary Outcome

The Visual analog scale is scored from 0-10, with 0 being not a problem and 10 being unbearable.

Interventions

  • DRUG Intranasal capsaicin
  • DRUG topical lidocaine

Trial Details

FieldValue
Enrollment Target 28 participants
Start Date 2019-09-10
Est. Completion 2023-11-30
Phase Phase 3

What the finished NCT05093478 record still lists

NCT05093478 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (96% lower).

The record links to 0 conditions, and to 2 interventions - of which Intranasal capsaicin is the first listed.

NCT05093478 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT05093478 about?

NCT05093478 is a clinical study titled "The Prevalence of Local Immunoglobulin E (IgE) Elevation and Its Effect on Intranasal Capsaicin Therapy in the Non-allergic Rhinitis Population". The purpose of this study to determine the therapeutic response of non-allergic rhinitis patients that have been subtyped as non-allergic rhinitis with local IgE elevation or non-allergic rhinopathy to intranasal capsaicin based on visual analog scale and optical rhinometry, to determine the prevale...

What is the current status of trial NCT05093478?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 28 participants. The study started on 2019-09-10. Estimated completion is 2023-11-30.

What interventions are being tested in trial NCT05093478?

The interventions under investigation include: Intranasal capsaicin (DRUG), topical lidocaine (DRUG).

Who is sponsoring clinical trial NCT05093478?

This trial is sponsored by The University of Texas Health Science Center, Houston, which has 732 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT05093478's enrollment target sits among peer trials

28 1935th of 2000 higher than 65 of 2,000 other Phase 3 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03471117 · 28 participants · Phase 4

    Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients

  • NCT03523975 · 28 participants · Phase 1

    Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma

  • NCT03608631 · 28 participants · Phase 1

    iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation

  • NCT03810651 · 28 participants · Early Phase 1

    Pencil Beam Scanning in Patients With Renal Tumors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05093478, the US trial registry maintained by the National Library of Medicine. NCT05093478 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.